Pharmaceutical major Aurobindo Pharma has informed that it has received tentative approval from the US Food and Drug Administration (USFDA) to market Efavirenz tablets, in the strength of 600 mg.

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used with other medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS).

Yesterday, the company received final approval from USFDA to market Cefazolin sodium injection, in the strengths of 500 mg / vial and 1 gram / vial.